Regulatory Story
Go to market news section View chart   Print
Informa PLC  -  INF   

Acquisition of Dove Medical Press

Released 07:00 26-Sep-2017

RNS Number : 8027R
Informa PLC
26 September 2017

Press Release

26 September 2017





Informa PLC

Informa extends open access position and capability with addition of Dove Medical Press


Key highlights

·      Open Access expansion…Addition of independent open access ("OA") publisher, Dove Medical Press, increases Informa's position and capability in the growing OA market;

·      Quality journal portfolioCollection of established and indexed journals takes Informa's OA journal portfolio to over 200 and total number of journals to more than 2,500;

·      Platform capabilityEstablished platform for identifying new subject categories, managing collaboration and peer review;

·      Attractive fit …Strengthens position in Health Sciences, including growth subjects such as oncology, ophthalmology, neuroscience and psychiatry;

London: Informa (LSE: INF.L), the International Exhibitions, Events, Business Intelligence and Academic Publishing Group, today announces the addition of Dove Medical Press, strengthening its capability and presence in open access publishing.

Stephen A. Carter, Informa Group Chief Executive, said: 

"The addition of Dove Medical Press adds strength and capability to our OA portfolio, further increasing choice and flexibility for researchers across a widening range of subject areas."

He added:

"Its track record, publishing platform and growing reputation in Health Sciences enhance our Journals business, strengthening our position in the attractive and growing OA market."

Dove Medical Press is an independent OA journals publisher, founded in 2003, producing a range of quality OA journals, mainly in Health Sciences, with additional content in Science and Technology. A large proportion of its journals are indexed by the Web of Science and PubMed and a growing number have established and improving impact factors. Leading titles include OncoTargets and Therapy, International Journal of Nanomedicine and Clinical Ophthalmology.

The addition of Dove Medical Press complements our growing portfolio of OA titles published under the Taylor & Francis and Cogent brands, enabling continued expansion in the attractive OA market. Following the acquisition, Informa will publish more than 200 OA journals, as part of a total journal portfolio of more than 2,500 titles, providing a valuable and growing alternative publishing outlet for authors.

Financial details were not disclosed but the transaction is expected to be modestly accretive to adjusted earnings in the first full year of ownership and deliver a return on investment ahead of the cost of capital within three years.



Informa PLC


Stephen A. Carter, Group Chief Executive

+44 (0) 20 7017 5771

Gareth Wright, Group Finance Director

+44 (0) 20 7017 7096

Richard Menzies-Gow, Director of Investor Relations

+44 (0) 20 3377 3445

Teneo Strategy


Tim Burt               / Zoe Watt

+44 (0) 20 7240 2486


Notes to editors

Informa Group PLC

Informa is a leading international Business Intelligence, Exhibitions, Events and Academic Publishing Group with annual revenues of over £1.6bn. It helps commercial, professional and academic communities work smarter and make better decisions faster, through specialist content and intelligence, and opportunities to connect and learn.

About Dove Medical Press, Ltd

Dove Medical Press Ltd is a privately held company specializing in the publication of Open Access peer-reviewed journals across the broad spectrum of science, technology and especially medicine.

Dove Press was founded in 2003 with the objective of combining the highest editorial standards with the 'best of breed' new publishing technologies. Dove Press has offices in Manchester and London in the United Kingdom, representatives in Princeton, New Jersey in the United States, and editorial offices in Auckland, New Zealand.





This information is provided by RNS
The company news service from the London Stock Exchange

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.


Acquisition of Dove Medical Press - RNS